Of the eight studies included in the present systematic review, seven studies were eligible for and were meta-analyzed, showing significantly higher circulating ANGPTL8 levels in patients with NAFLD or MAFLD (six and one study for the NAFLD or MAFLD diagnosis, respectively) compared to controls (SMD: 0.62, 95% CI: 0.28, 0.97, p < 0.001). This evidence concerns the gene ANGPTL8 and metabolic dysfunction-associated steatotic liver disease.